- Home
- AHG vs ELDN Comparison
AHG vs ELDN Comparison
Compare AHG & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- ELDN
- Stock Information
- Founded
- AHG 2013
- ELDN 2004
- Country
- AHG China
- ELDN United States
- Employees
- AHG N/A
- ELDN N/A
- Industry
- AHG Business Services
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- ELDN Health Care
- Exchange
- AHG Nasdaq
- ELDN Nasdaq
- Market Cap
- AHG 240.9M
- ELDN 104.0M
- IPO Year
- AHG N/A
- ELDN N/A
- Fundamental
- Price
- AHG $1.01
- ELDN $2.54
- Analyst Decision
- AHG
- ELDN Strong Buy
- Analyst Count
- AHG 0
- ELDN 3
- Target Price
- AHG N/A
- ELDN $11.67
- AVG Volume (30 Days)
- AHG 6.9K
- ELDN 48.7K
- Earning Date
- AHG 09-17-2024
- ELDN 08-18-2024
- Dividend Yield
- AHG N/A
- ELDN N/A
- EPS Growth
- AHG N/A
- ELDN N/A
- EPS
- AHG N/A
- ELDN N/A
- Revenue
- AHG $2,414,338.00
- ELDN N/A
- Revenue This Year
- AHG N/A
- ELDN N/A
- Revenue Next Year
- AHG N/A
- ELDN N/A
- P/E Ratio
- AHG N/A
- ELDN N/A
- Revenue Growth
- AHG N/A
- ELDN N/A
- 52 Week Low
- AHG $0.53
- ELDN $1.07
- 52 Week High
- AHG $2.90
- ELDN $3.35
- Technical
- Relative Strength Index (RSI)
- AHG 52.89
- ELDN 35.62
- Support Level
- AHG $0.99
- ELDN $2.71
- Resistance Level
- AHG $1.11
- ELDN $2.92
- Average True Range (ATR)
- AHG 0.06
- ELDN 0.17
- MACD
- AHG -0.00
- ELDN -0.04
- Stochastic Oscillator
- AHG 37.50
- ELDN 20.69
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.